Could a diabetes drug and a blood pressure pill shield vasculitis patients from heart attacks?

NCT ID NCT06887062

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether two drugs—bosentan and dapagliflozin—can improve blood vessel function in people with large vessel vasculitis, a condition that damages arteries and raises the risk of heart attacks and strokes. Sixty adults with stable disease will take both drugs for 6 weeks, then dapagliflozin alone for 4 weeks. Researchers will measure changes in blood flow and blood pressure to see if the combination helps protect the cardiovascular system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Bosentan and dapagliflozin
What this could lead to
If it works, this could point toward a new way to lower heart attack and stroke risk in people with large vessel vasculitis.
What could go wrong
This is a small, early-phase trial with only 60 participants and no placebo group, so results may not be conclusive. The drugs may cause side effects like liver issues or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis Inflammation Takayasu arteritis temporal arteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Edinburgh

    RECRUITING

    Edinburgh, EH16 4TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.